Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 614

Next Previous
Drug Profile

PF 614

Alternative Names: BIO-MD™ PF614; ER Oxycodone - Ensysce Biosciences; ER Oxycodone Bio-MD™ System; Oxycodone prodrug extended release - Ensysce Biosciences; PF614; PF614-TAAP™; PRF 06014; PRF-06104

Latest Information Update: 08 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PharmacoFore
  • Developer Ensysce Biosciences
  • Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Pain

Most Recent Events

  • 10 Mar 2025 Ensysce Biosciences plans a phase III trial for Postoperative pain (PO) in the second quarter of 2025
  • 10 Mar 2025 Ensysce Biosciences announces intention to submit NDA to US FDA for Pain in 2026
  • 24 Nov 2024 Ensysce Biosciences initiates a phase I trial for Pain (In volunteers) in USA (PO, capsule) (NCT06500793)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top